"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
Descriptor ID |
D010880
|
MeSH Number(s) |
D03.383.621
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1996 | 1 | 1 | 2 |
1998 | 3 | 0 | 3 |
1999 | 3 | 1 | 4 |
2000 | 5 | 0 | 5 |
2001 | 7 | 1 | 8 |
2002 | 0 | 2 | 2 |
2003 | 11 | 5 | 16 |
2004 | 7 | 2 | 9 |
2005 | 10 | 7 | 17 |
2006 | 6 | 7 | 13 |
2007 | 14 | 1 | 15 |
2008 | 9 | 7 | 16 |
2009 | 10 | 6 | 16 |
2010 | 5 | 4 | 9 |
2011 | 8 | 5 | 13 |
2012 | 6 | 9 | 15 |
2013 | 9 | 11 | 20 |
2014 | 7 | 19 | 26 |
2015 | 9 | 28 | 37 |
2016 | 6 | 23 | 29 |
2017 | 9 | 21 | 30 |
2018 | 3 | 41 | 44 |
2019 | 12 | 34 | 46 |
2020 | 13 | 14 | 27 |
2021 | 18 | 14 | 32 |
2022 | 2 | 14 | 16 |
2023 | 2 | 6 | 8 |
2024 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 Apr 09; 8(7):1639-1650.
-
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 Feb 27; 8(4):842-845.
-
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J Immunother Cancer. 2024 Feb 05; 12(2).
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885.
-
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec; 8(6):101609.
-
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med. 2023 Nov 16; 389(20):1851-1861.